8-K: ImmuCell and Norbrook Amend Supply Agreement, Set Termination Date for Re-Tain Product

ImmuCell Corporation and Norbrook Laboratories Limited have amended their supply agreement, setting a termination date of November 30, 2024, for their Re-Tain product collaboration.

Summary

• ImmuCell Corporation and Norbrook Laboratories Limited have agreed to amend their existing Development Services and Commercial Supply Agreement.
• The amendment sets a termination date of November 30, 2024, for the agreement, unless terminated earlier.
• The agreement pertains to Norbrook providing formulation, aseptic filling, and packaging services for ImmuCell's Re-Tain product, a treatment for subclinical mastitis in dairy cows.
• The amendment also modifies payment terms, with 75% of the total amount produced to be invoiced monthly during production, and the remaining 25% upon dispatch after FDA approval.
• If FDA approval for Re-Tain is not received by November 30, 2024, the agreement will expire, and Norbrook will invoice ImmuCell for the final balance.
• The agreement includes updated schedules for production timelines, targeting approximately 160,000 releasable commercial units with expiry dates in late 2025 to early 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative due to the termination clause, but the agreement provides clarity on timelines and payment terms. The risk of termination is a concern, but the agreement is a necessary step in the product's development.

Positives

• The amendment clarifies payment terms and provides a clear timeline for the agreement.
• The updated production schedule provides a target for the number of commercial units and their expiry dates.
• The agreement ensures that Norbrook will be paid for services rendered even if FDA approval is not received by the deadline.

Negatives

• The agreement will automatically terminate if FDA approval for Re-Tain is not received by November 30, 2024.
• The termination of the agreement could impact the future availability of the Re-Tain product.

Risks

• The primary risk is the potential failure to obtain FDA approval for Re-Tain by November 30, 2024, which would terminate the agreement.
• The termination of the agreement could lead to supply chain disruptions for the Re-Tain product.
• There is a risk that the updated production schedule may not be met, impacting the availability of commercial units.

Future Outlook

The future of the Re-Tain product supply is dependent on obtaining FDA approval by November 30, 2024. If approval is not received, the agreement will terminate, potentially impacting the product's availability.

Management Comments

• Michael F. Brigham, President and CEO of ImmuCell, signed the Amending Agreement on behalf of the company.

Industry Context

This agreement is typical in the pharmaceutical industry, where companies often contract with specialized manufacturers for production and packaging. The amendment reflects the need to adjust timelines and payment terms based on regulatory milestones.

Comparison to Industry Standards

• Contract manufacturing agreements are common in the pharmaceutical industry, with companies like Catalent and Lonza providing similar services.
• The payment terms, with a portion due upon production and the remainder upon dispatch, are standard practice.
• The inclusion of a termination clause based on regulatory approval timelines is also a common risk mitigation strategy.
• The target of 160,000 commercial units is a specific production goal, which is typical for a product launch.

Stakeholder Impact

• Shareholders may be concerned about the potential termination of the agreement if FDA approval is not received.
• Employees involved in the Re-Tain project may be affected by the outcome of the FDA approval process.
• Customers, primarily dairy farmers, will be impacted by the availability of the Re-Tain product.
• Norbrook's revenue will be affected by the termination of the agreement if FDA approval is not received.

Next Steps

• ImmuCell needs to secure FDA approval for Re-Tain by November 30, 2024, to avoid termination of the agreement.
• Norbrook will continue production of Re-Tain according to the updated schedule.
• ImmuCell will need to manage the supply chain and distribution of the product upon FDA approval.

Key Dates

Keywords

ImmuCell, Norbrook, Re-Tain, FDA approval, supply agreement, mastitis, dairy cows, pharmaceutical manufacturing, contract manufacturing, aseptic filling